Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.37 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 4/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30793321 | 0.88 | HTT (0.33) | CXCR4PDCD1CD274KMT2A | |
| SCHEMBL30793781 | 0.86 | CXCR4 (0.31) | CXCR4PDCD1CD274GRM5 | |
| SCHEMBL30793328 | 0.80 | GRM5 (0.37) | CXCR4PDCD1CD274GRM5 | |
| SCHEMBL31739519 | 0.80 | CXCR4 (0.33) | CXCR4PDCD1CD274 | |
| SCHEMBL30793898 | 0.80 | MALT1 (0.37) | MALT1GRIA2PDCD1CD274 | |
| SCHEMBL24536069 | 0.78 | PDCD1 (0.36) | CXCR4PDCD1CD274 | |
| SCHEMBL30793834 | 0.78 | PDCD1 (0.31) | PDCD1CD274 | |
| SCHEMBL24537276 | 0.77 | MAP4K4 (0.37) | CXCR4PDCD1CD274 | |
| SCHEMBL30793562 | 0.77 | PDCD1 (0.34) | CXCR4GRIA2PDCD1CD274GRM5 | |
| SCHEMBL30793751 | 0.77 | KDM4E (0.34) | PDCD1CD274KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368649-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368649-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | NPSR1 4583/4885MALT1 1339/4885CXCR4 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.